Gastrointestinal ultrasound in inflammatory bowel disease: experience from the Chinese IBD Elite Union

Mao, Ren; Chen, Yujun; Xie, Xian-Jin; Chen, Minhu

doi:10.1136/gutjnl-2018-317070

Cited by 4 publications

(6 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fecal microbiata transplant donors are a special group with potential for widespread transmission of the disease, and testing for viral RNA in their stool samples should be seriously considered, especially if they have a history of typical COVID-19 symptoms over the past 4 to 6 wk [33] . Finally, it is reasonable to consider the donors and recipients of liver transplantation as a special population and recommend universal testing for SARS-CoV-2 before liver transplantation [34] . As mentioned above, given reports of a small minority of patients initially presenting exclusively with GI symptoms, it is important for GI consultants to remain vigilant and include COVID-19 in their differential diagnosis even in the absence of respiratory symptoms, especially in febrile patients.…”

Section: Testing and Fecal Sheddingmentioning

confidence: 99%

SARS-COV-2 infection (coronavirus disease 2019) for the gastrointestinal consultant

Hajifathalian

Mahadev

Schwartz

et al. 2020

WJG

View full text Add to dashboard Cite

The current pandemic due to the severe acute respiratory syndrome coronavirus 2 has caused an extreme burden for health care systems globally, and the number of cases is expected to continue to increase, at least in the immediate future. The virus is estimated to have infected more than 1.5 million individuals. The available reports suggest that gastrointestinal (GI) involvement in coronavirus disease 2019 (COVID-19) is common and in some cases the GI symptoms may precede the respiratory symptoms. In addition to direct effects of severe acute respiratory syndrome coronavirus 2, the infected patients remain at risk for the complications commonly managed by gastroenterology and hepatology consultants. The most commonly reported GI manifestation of COVID-19 is diarrhea, which is reported in a third to up to more than half of the patients. Mild to moderate elevation of the liver enzymes are also common, although no case of acute liver failure has been reported so far. Many of the medications used for treatment of COVID-19 can also be associated with GI symptoms or liver injury and can be included in the differential diagnosis in these patients. Although the diagnosis of the infection is currently based on RNA analysis in respiratory samples, the available literature on fecal shedding of this virus suggests that fecal RNA testing might prove to be a useful diagnostic test. It is reasonable to delay all non-urgent endoscopic procedures during the peak of the pandemic and use additional protective equipment such as N95 respirators during endoscopy while most patients can be considered high risk for having been exposed to the virus.

show abstract

Section: Testing and Fecal Sheddingmentioning

confidence: 99%

SARS-COV-2 infection (coronavirus disease 2019) for the gastrointestinal consultant

Hajifathalian

Mahadev

Schwartz

et al. 2020

WJG

View full text Add to dashboard Cite

show abstract

“…In a study with 1099 patients, 83.2% had lymphopenia, 36.2% thrombocytopenia, and 33.7% leukopenia. In contrast, an increase in ALT and AST levels was found, indicating liver injury, especially in severe cases [2,8,[11][12][13].…”

Section: Hematological and Hepatic Changesmentioning

confidence: 99%

“…Some studies have revealed the presence of mild steatosis, attributed mainly to drug-induced liver damage and not to the virus [12,13]. Also, inflammation mediated by the immune system, such as cytokine storm and hypoxia associated with pneumonia, contributes to mild liver damage or liver failure in severely affected patients with COVID-19 [8].…”

Section: Hematological and Hepatic Changesmentioning

confidence: 99%

“…Also, inflammation mediated by the immune system, such as cytokine storm and hypoxia associated with pneumonia, contributes to mild liver damage or liver failure in severely affected patients with COVID-19 [8]. There is evidence that the virus can replicate in the liver and influence normal liver functions, as well as multiple respiratory infections [13,14]. Xie et al observed among hospitalized patients with moderate COVID-19 (without the need for intensive care or mechanical ventilation), there was an increase in transaminases above 30%, with an elevation of AST slightly higher than that of ALT (35.4% x 31, 6%, respectively).…”

Section: Hematological and Hepatic Changesmentioning

confidence: 99%

“…Patients with previous hepatitis B or C infected with COVID-19 are more likely to develop severe hepatitis, just as patients with cirrhosis are more susceptible to the development of severe immunodeficiency infection [6,8,13]. Liver disease patients have a leukocytosis with neutrophilia and elevated C-Reactive Protein compared to others, who develop leukopenia and lymphocytosis more commonly [15].…”

Section: Hepatopathy/risk Factormentioning

confidence: 99%

See 2 more Smart Citations

COVID-19 and Liver injury: hepatology perspectives

Filho¹

2020

CMRR

View full text Add to dashboard Cite

SARS-CoV-2, a severe acute respiratory syndrome caused by Coronavirus 2, discovered in 2019 in China, is responsible for the current pandemic declared by the WHO since March 2020. The clinical syndrome caused by Covid-19 has a broad spectrum of severity. The most common clinical manifestations are fever, dry cough, dyspnea, fatigue, and anosmia. The virus binds to receptors for angiotensin-converting enzyme 2 (ECA2) and serine protease TMPRSS2 for protein S initiation, which are expressed not only in the lungs but also in the liver, colonic, esophageal and biliary epithelial cells. In this context, the liver is a potential target for COVID-19 infection. Liver damage occurs during the course and treatment of viral infection in patients with or without previous liver disease. Therefore, the characteristics of liver injury associated with COVID-19 were reviewed based on research related, in the context of the pandemic.

show abstract

Machine learning for selecting patients with Crohn's disease for abdominopelvic computed tomography in the emergency department

Konikoff

Goren

Yalon

et al. 2021

Digestive and Liver Disease

View full text Add to dashboard Cite

Gastrointestinal ultrasound in inflammatory bowel disease: experience from the Chinese IBD Elite Union

Cited by 4 publications

References 6 publications

SARS-COV-2 infection (coronavirus disease 2019) for the gastrointestinal consultant

SARS-COV-2 infection (coronavirus disease 2019) for the gastrointestinal consultant

COVID-19 and Liver injury: hepatology perspectives

Machine learning for selecting patients with Crohn's disease for abdominopelvic computed tomography in the emergency department

Contact Info

Product

Resources

About